346 related articles for article (PubMed ID: 36168623)
1. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
[TBL] [Abstract][Full Text] [Related]
2. Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands.
Kuo HT; Zhang Z; Zhang C; Merkens H; Tan R; Wong AAWL; Uribe CF; Bénard F; Lin KS
Theranostics; 2023; 13(13):4559-4573. PubMed ID: 37649602
[TBL] [Abstract][Full Text] [Related]
3.
Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
[TBL] [Abstract][Full Text] [Related]
4. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of a novel urea-based
Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
[TBL] [Abstract][Full Text] [Related]
6. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
7. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
8. Improve the Biodistribution with Bulky and Lipophilic Modification Strategies on Lys-Urea-Glu-Based PSMA-Targeting Radiotracers.
Cai P; Tang S; Xia L; Wang Y; Liu Y; Feng Y; Liu N; Chen Y; Zhou Z
Mol Pharm; 2023 Feb; 20(2):1435-1446. PubMed ID: 36696174
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Evaluation of
Lu K; Zhang C; Zhang Z; Kuo HT; Colpo N; Bénard F; Lin KS
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446782
[TBL] [Abstract][Full Text] [Related]
10. Effects of Linker Modification on Tumor-to-Kidney Contrast of
Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108
[No Abstract] [Full Text] [Related]
11. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
12. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
[TBL] [Abstract][Full Text] [Related]
14. Monosodium Glutamate Reduces
Rousseau E; Lau J; Kuo HT; Zhang Z; Merkens H; Hundal-Jabal N; Colpo N; Lin KS; Bénard F
J Nucl Med; 2018 Dec; 59(12):1865-1868. PubMed ID: 30097503
[TBL] [Abstract][Full Text] [Related]
15. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.
Gourni E; Canovas C; Goncalves V; Denat F; Meyer PT; Maecke HR
PLoS One; 2015; 10(12):e0145755. PubMed ID: 26700033
[TBL] [Abstract][Full Text] [Related]
16. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.
Kelly J; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; Schlyer D; Zhao Y; Kim D; Babich JW
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1841-1851. PubMed ID: 29623376
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
18. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
19. In Vitro and In Vivo Characterization of an
Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]